Please use this identifier to cite or link to this item:
http://hdl.handle.net/123456789/29398
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Nur Najihah Izzati Mat Rani | - |
dc.contributor.author | Alzubaidi, Zahraa M | - |
dc.contributor.author | Butt, Adeel Masood | - |
dc.contributor.author | Nur Dini Fatini Mohammad Faizal | - |
dc.contributor.author | Sekar, Mahendran | - |
dc.contributor.author | Hanisah Azhari | - |
dc.contributor.author | Mohd Cairul Iqbal Mohd Amin | - |
dc.contributor.author | (UniKL RCMP) | - |
dc.date.accessioned | 2023-12-28T02:46:47Z | - |
dc.date.available | 2023-12-28T02:46:47Z | - |
dc.date.issued | 2022-07 | - |
dc.identifier.citation | Nur Njihah Izzati Abdul Rani, Alzubaidi, Z. M., Butt, A. M., Faizal, Nur Dini Fatini Mohammad Faizal, Sekar, M., Hanisah Azhari, & Mohd Cairul Iqbal Mohd Amin (2022). Outer membrane vesicles as biomimetic vaccine carriers against infections and cancers. WIREs Nanomedicine and Nanobiotechnology, 14(4). https://doi.org/10.1002/wnan.1784 | en_US |
dc.identifier.issn | 19395116 | - |
dc.identifier.uri | https://ir.unikl.edu.my/jspui/handle/123456789/29398 | - |
dc.description.abstract | In the last decade, nanoparticle-based therapeutic modalities have emerged as promising treatment options for cancer and infectious diseases. To improve prognosis, chemotherapeutic and antimicrobial drugs must be delivered selectively to the target sites. Researchers have increasingly focused their efforts on improving drug delivery, with a particular emphasis on cancer and infectious diseases. When drugs are administered systemically, they become diluted and can diffuse to all tissues but only until the immune system intervenes and quickly removes them from circulation. To enhance and prolong the systemic circulation of drugs, nanocarriers have been explored and used; however, nanocarriers have a major drawback in that they can trigger immune responses. Numerous nanocarriers for optimal drug delivery have been developed using innovative and effective biointerface technologies. Autologous cell-derived drug carriers, such as outer membrane vesicles (OMVs), have demonstrated improved bioavailability and reduced toxicity. Thus, this study investigates the use of biomimetic OMVs as biomimetic vaccine carriers against infections and cancers to improve our understanding in the field of nanotechnology. In addition, discussion on the advantages, disadvantages, and future prospects of OMVs will also be explored. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Therapeutic Approaches and Drug Discovery > Nanomedicine for Infectious Disease Biology-Inspired Nanomaterials > Protein and Virus-Based Structures. | en_US |
dc.language.iso | en | en_US |
dc.publisher | John Wiley and Sons Inc | en_US |
dc.subject | Biomimetics | en_US |
dc.subject | Cancer | en_US |
dc.subject | Drug delivery | en_US |
dc.subject | Infections | en_US |
dc.subject | OMVs | en_US |
dc.subject | Vaccines | en_US |
dc.title | Outer membrane vesicles as biomimetic vaccine carriers against infections and cancers | en_US |
dc.type | Article | en_US |
Appears in Collections: | Journal Articles |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Outer membrane vesicles as biomimetic vaccine carriers against infections and cancers.pdf | 69.43 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.